Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 28 #1
TickerOGEN [AMEX]
CompanyOragenics Inc.
CountryUSA
IndustryBiotechnology
Market Cap39.84MEPS (ttm)-0.22
P/E-EPS this Y24.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y30.40%
P/S33.20EPS next 5Y-
P/B3.44EPS Q/Q91.20%
Dividend-Sales Q/Q-33.30%
Insider Own2.30%Inst Own41.20%
Insider Trans15.69%Inst Trans0.26%
Short Float0.13%EarningsNov 11
Analyst Recom1.00Target Price7.00
Avg Volume25.72K52W Range0.79 - 4.65
Nov-05-14 07:08PM10-Q for Oragenics, Inc. Company Spotlight
Nov-03-14 04:14PMORAGENICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-31-14 06:03AMORAGENICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Oct-30-14 07:49PMOragenics, Inc. Announces Change in Management and Board of Directors Business Wire
Oct-15-14 04:33PM3 Health Care Stocks Pushing The Sector Higher at TheStreet
Oct-15-14 04:33PM3 Drugs Stocks Pushing The Industry Higher at TheStreet
Sep-10-14 07:45AMOragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion Business Wire
Aug-20-14 01:04PMORAGENICS INC Financials EDGAR Online Financials
Aug-07-14 04:08PMORAGENICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Jun-11-14 06:39AMOragenics (OGEN) in Focus: Stock Adds 6% in Session Zacks
Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. It develops and markets probiotic products comprising ProBiora3, an oral care probiotics that promote oral health for humans and pets under the Evora and ProBiora brands in approximately 13 countries worldwide. The company's ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. Its product candidates consists of LPT3-04, a naturally occurring compound for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140-S, an antibiotic product candidate in preclinical testing for healthcare-associated infections. Oragenics, Inc. offers its ProBiora3 products through direct-to-consumer channels, professional offices, and private label partnerships. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KOSKI FAMILY LP10% OwnerNov 19Buy0.8524,54620,845662,524Nov 20 04:07 PM
Telling FredDirectorNov 14Buy0.9527,00025,541266,174Nov 17 04:06 PM
KOSKI FAMILY LP10% OwnerNov 13Buy0.8413,00010,880637,978Nov 17 04:05 PM
KOSKI FAMILY LP10% OwnerNov 12Buy0.8515,10012,848624,978Nov 13 04:06 PM
KOSKI FAMILY LP10% OwnerNov 11Buy0.856,0005,099609,878Nov 12 04:06 PM
TickerCANF [AMEX]
CompanyCan-Fite BioPharma Ltd.
CountryIsrael
IndustryBiotechnology
Market Cap42.48MEPS (ttm)-0.89
P/E-EPS this Y29.50%
Forward P/E-EPS next Y39.50%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B11.71EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.66%Earnings-
Analyst Recom2.00Target Price17.50
Avg Volume286.36K52W Range2.29 - 9.46
Nov-19-14 07:30AMSmall Cap IR Initiates Coverage of Can-Fite Biopharma: Newly Discovered Late Clinical Stage BioPharma Vendor with Potentially Revolutionary Breakthroughs PR Newswire
Nov-18-14 07:39AMCoverage initiated on Can-Fite BioPharma by H.C. Wainwright Briefing.com
Nov-18-14 07:00AMCan-Fite Near-Term Milestones Timetable for 2014/2015 PR Newswire
Nov-17-14 05:48PMCan-Fite Announces Special General Meeting of Shareholders to Elect External Director PR Newswire
Nov-13-14 07:00AMCan-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting PR Newswire
Oct-30-14 07:00AMCan-Fite to Participate in BIO-Europe International Partnering Conference PR Newswire
Oct-20-14 04:32PM3 Stocks Pushing The Drugs Industry Lower at TheStreet
Oct-15-14 08:11AMCorcept Therapeutics (CORT) Jumps: Stock Rises 6.4% Zacks
Oct-07-14 07:00AMCan-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session PR Newswire
Sep-30-14 07:00AMU.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery PR Newswire
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.
TickerFATE [NASD]
CompanyFate Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap87.01MEPS (ttm)-1.25
P/E-EPS this Y72.90%
Forward P/E-EPS next Y-3.20%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B2.58EPS Q/Q93.30%
Dividend-Sales Q/Q-
Insider Own33.43%Inst Own81.40%
Insider Trans-0.01%Inst Trans2.54%
Short Float0.28%EarningsNov 11
Analyst Recom1.80Target Price12.67
Avg Volume13.83K52W Range3.53 - 13.55
Nov-21-14 01:04PMFATE THERAPEUTICS INC Financials EDGAR Online Financials
Nov-19-14 06:07AMFate Therapeutics (FATE) Catches Eye: Stock Adds 6.4% in Session Zacks
Nov-17-14 06:01AMFATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online
Nov-12-14 09:01AMFATE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh EDGAR Online
Nov-11-14 05:00PMFate Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today CCBN
Nov-11-14 04:12PMFate Therapeutics posts 3Q loss AP
Nov-11-14 04:01PMFate Therapeutics Reports Third Quarter 2014 Financial Results GlobeNewswire
Nov-11-14 07:07AMQ3 2014 Fate Therapeutics Inc Earnings Release - Time Not Supplied CCBN
Nov-04-14 04:01PMFate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014 GlobeNewswire
Oct-30-14 07:01AMFate Therapeutics to Present at Nomura Biotechnology Conference GlobeNewswire
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn Peter DSee remarksJun 12Option Exercise1.615,4718,8089,510Jun 12 05:45 PM
Flynn Peter DSee remarksJun 12Sale7.005,47138,2974,039Jun 12 05:45 PM
Flynn Peter DSee remarksJun 11Option Exercise1.631,0171,6585,056Jun 12 05:45 PM
Flynn Peter DSee remarksJun 11Sale7.001,0177,1194,039Jun 12 05:45 PM
Flynn Peter DSee remarksJun 10Option Exercise1.636991,1395,389Jun 11 05:58 PM
TickerROIAK [NASD]
CompanyRadio One Inc.
CountryUSA
IndustryBroadcasting - Radio
Market Cap92.80MEPS (ttm)-1.38
P/E-EPS this Y2.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y16.20%
P/S0.21EPS next 5Y-
P/B2.72EPS Q/Q0.00%
Dividend-Sales Q/Q-5.20%
Insider Own40.10%Inst Own42.90%
Insider Trans11.07%Inst Trans-0.25%
Short Float11.21%EarningsNov 12/b
Analyst Recom1.00Target Price2.25
Avg Volume144.98K52W Range1.50 - 5.82
Nov-17-14 07:09PM10-Q for Radio One, Inc. Company Spotlight
Nov-12-14 10:00AMRadio One Inc Earnings Call scheduled for 10:00 am ET today CCBN
Nov-12-14 07:07AMQ3 2014 Radio One Inc Earnings Release - Before Market Open CCBN
Nov-12-14 06:00AMRadio One, Inc. Reports Third Quarter Results PR Newswire
Oct-16-14 10:30AMRadio One, Inc. Third Quarter 2014 Results Conference Call PR Newswire
Oct-01-14 07:00AM4 Stocks Under $10 to Trade for Breakouts at TheStreet
Aug-05-14 10:00AMRadio One Earnings Call scheduled for 10:00 am ET today CCBN
Aug-05-14 06:45AMRadio One, Inc. Reports Second Quarter Results PR Newswire
Jul-23-14 11:51AMRadio One, Inc. Second Quarter 2014 Results Conference Call PR Newswire
Jun-19-14 10:00AMRadio One, Inc. Announces Class D Shares included on a Preliminary List of Additions to Russell Indices PR Newswire
Radio One, Inc., together with its subsidiaries, operates as an urban-oriented multi-media company in the United States. The company operates through four segments: Radio Broadcasting, Reach Media, Internet, and Cable Television. The Radio Broadcasting segment is engaged in the radio broadcasting operations that primarily targets African-American and urban listeners. As of December 31, 2013, it owned and operated 54 broadcast stations located in 16 urban markets. The Reach Media segment is involved in the operation of the Tom Joyner Morning Show; and other syndicated programming assets comprising The Rickey Smiley Morning Show, The Russ Parr Morning Show, The Yolanda Adams Morning Show, The James Fortune Show, and The Reverend Al Sharpton Show. The Internet segment is engaged in online business, including the operation of Interactive One, an online platform that provides social content, news, information, and entertainment through branded sites, such as News One, UrbanDaily, and HelloBeautiful; and online social networking Websites, including BlackPlanet and MiGente. The Cable Television segment operates an African-American targeted cable television network. The company was founded in 1980 and is based in Silver Spring, Maryland.
TickerBIND [NASD]
CompanyBIND Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap124.88MEPS (ttm)-1.94
P/E-EPS this Y-16.10%
Forward P/E-EPS next Y60.50%
PEG-EPS past 5Y0.00%
P/S13.14EPS next 5Y-
P/B2.69EPS Q/Q83.70%
Dividend-Sales Q/Q-26.10%
Insider Own2.10%Inst Own42.90%
Insider Trans-0.29%Inst Trans-1.47%
Short Float6.79%EarningsMay 08/b
Analyst Recom1.80Target Price23.33
Avg Volume118.13K52W Range7.50 - 15.77
Nov-21-14 06:12AMWeakness Seen in BIND Therapeutics: Stock Falls 9.4% Zacks
Nov-19-14 04:30PMThe S&P failed to extend its 4-day winning streak following headlines out of the Fed Yahoo Finance Blogs
Nov-19-14 07:00AMBIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium Business Wire
Nov-15-14 01:04PMBIND THERAPEUTICS, INC Financials EDGAR Online Financials
Nov-10-14 07:10AMBIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% Zacks
Nov-06-14 11:22AMBind Therapeutics posts 3Q loss AP
Nov-06-14 07:40AMBIND THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online
Nov-06-14 07:30AMBIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update Business Wire
Nov-06-14 07:25AMBIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin Nanomedicines for Oncology Business Wire
Nov-05-14 04:36PMBIND THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company's lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
TickerREI [AMEX]
CompanyRing Energy, Inc.
CountryUSA
IndustryOil & Gas Drilling & Exploration
Market Cap345.16MEPS (ttm)0.32
P/E41.94EPS this Y85.70%
Forward P/E15.01EPS next Y215.90%
PEG1.13EPS past 5Y19.70%
P/S10.40EPS next 5Y37.00%
P/B2.48EPS Q/Q700.00%
Dividend-Sales Q/Q289.30%
Insider Own1.20%Inst Own37.20%
Insider Trans30.98%Inst Trans15.19%
Short Float5.81%Earnings-
Analyst Recom1.80Target Price21.50
Avg Volume123.31K52W Range10.55 - 20.61
Nov-24-14Downgrade Canaccord Genuity Buy → Hold $20 → $12
Nov-24-14 08:43AMRing Energy downgraded by Canaccord Genuity Briefing.com
Nov-14-14 01:04PMRING ENERGY, INC. Financials EDGAR Online Financials
Nov-06-14 09:42AMRing Energy misses 3Q profit forecasts AP
Nov-06-14 09:30AMRing Energy, Inc. Announces Third Quarter and Nine Month 2014 Financial and Operating Results Business Wire
Nov-06-14 06:04AMRING ENERGY, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-07-14 09:30AMRing Energy, Inc. Provides Third Quarter 2014 Operations Update Business Wire
Aug-08-14 10:56AMRING ENERGY, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-08-14 09:30AMRing Energy Announces Second Quarter and Six Month 2014 Financial and Operating Results Business Wire
Jul-17-14 01:48PMComparing The Reynolds & Lorillard Merger With Comcast & Time Warner Benzinga
Jul-15-14 09:30AMRing Energy, Inc. Provides Second Quarter 2014 Operations Update Business Wire
Ring Energy, Inc. is engaged in the exploration, development, and production of oil and gas in Texas and Kansas. As of December 31, 2013, the company's proven reserves consisted of 7.3 million barrel of oil equivalent. It also has interests in approximately 3,482 gross developed acres and 10,893 gross undeveloped acres in Texas; and 16,997 gross acres in Kansas. Ring Energy, Inc. sells its oil and natural gas production to end users, marketers, and other purchasers. The company was formerly known as Transglobal Mining Corp. and changed its name to Ring Energy, Inc. in March 2008. Ring Energy, Inc. was founded in 2004 and is headquartered in Midlands, Texas.
TickerGALE [NASD]
CompanyGalena Biopharma, Inc.
CountryUSA
IndustryBiotechnology
Market Cap251.40MEPS (ttm)-0.70
P/E-EPS this Y-60.40%
Forward P/E-EPS next Y13.90%
PEG-EPS past 5Y4.90%
P/S33.97EPS next 5Y-
P/B7.96EPS Q/Q54.50%
Dividend-Sales Q/Q33.30%
Insider Own0.40%Inst Own18.30%
Insider Trans2.53%Inst Trans-2.90%
Short Float16.27%EarningsNov 03/a
Analyst Recom2.40Target Price6.00
Avg Volume1.50M52W Range1.56 - 7.77
Nov-24-14 09:39AMGalena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing at TheStreet
Nov-20-14 04:21PMGALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib EDGAR Online
Nov-20-14 04:20PMGalena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC GlobeNewswire
Nov-20-14 10:05AMUPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided Benzinga
Nov-18-14 07:05AMGalena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial GlobeNewswire
Nov-14-14 01:04PMGALENA BIOPHARMA, INC. Financials EDGAR Online Financials
Nov-13-14 07:05AMGalena Biopharma to Present at the Stifel 2014 Healthcare Conference GlobeNewswire
Nov-11-14 07:05AMGalena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients GlobeNewswire
Nov-07-14 05:26PMGALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-07-14 04:28PMAnother lackluster session for major equities Yahoo Finance Blogs
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company's lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chin RichardDirectorFeb 12Option Exercise1.59187,500297,625187,500Feb 13 07:56 PM
Chin RichardDirectorFeb 12Sale4.33187,500812,4380Feb 13 07:56 PM
Nisi RudolphDirectorFeb 07Buy4.9420,00098,74223,500Feb 13 08:22 PM
GALLIKER STEPHEN SDirectorFeb 03Option Exercise1.33300,000397,500310,000Feb 05 07:41 PM
GALLIKER STEPHEN SDirectorFeb 03Sale4.18300,0001,253,04010,000Feb 05 07:41 PM
TickerAG [NYSE]
CompanyFirst Majestic Silver Corp.
CountryCanada
IndustrySilver
Market Cap616.77MEPS (ttm)-0.67
P/E-EPS this Y-76.80%
Forward P/E14.58EPS next Y176.90%
PEG-EPS past 5Y-58.29%
P/S2.66EPS next 5Y46.80%
P/B1.06EPS Q/Q-
Dividend-Sales Q/Q-47.00%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float2.05%Earnings-
Analyst Recom2.60Target Price8.39
Avg Volume1.71M52W Range4.61 - 12.45
Nov-24-14 10:05AMFirst Majestic Silver (AG) Stock: Weak On High Volume Today at TheStreet
Nov-20-14 10:00AMFirst Majestic Silver (AG) Is Today's Strong On High Volume Stock at TheStreet
Nov-20-14 05:43AMFirst Majestic Silver (AG) in Focus: Stock Falls 7.3% Zacks
Nov-19-14 09:52AMFirst Majestic Silver (AG) Showing Signs Of Perilous Reversal Today at TheStreet
Nov-19-14 06:38AMTractor makers feel the pinch as farm commodity prices fall at Financial Times
Nov-17-14 09:03AMFirst Majestic Silver (AG) Downgraded From Hold to Sell at TheStreet
Nov-12-14 09:45AMPerilous Reversal Stock: First Majestic Silver (AG) at TheStreet
Nov-12-14 08:00AMFirst Majestic posts 3Q loss AP
Nov-12-14 07:00AMFirst Majestic Reports Third Quarter Financial Results PR Newswire
Nov-12-14 07:00AMFirst Majestic Reports Third Quarter Financial Results CNW Group
First Majestic Silver Corp. acquires, develops, and explores mineral properties with a focus on silver projects in Mxico. The company owns and operates five producing mines, including the La Encantada silver mine in Coahuila State, the La Parrilla silver mine in Durango State, the San Martin silver mine in Jalisco State, the La Guitarra silver mine in Mxico State, and the Del Toro silver mine in Zacatecas State; and two advanced-stage development silver projects, such as the La Luz silver project in San Luis Potosi State and the Plomosas silver project in Sinaloa State. It also owns and operates four exploration projects comprising the Peasco Quemado silver project in Sonora State, the La Frazada silver project in Nayarit State, and the Los Lobos silver project in Sonora State; and has interest in certain exploration properties in Jalisco State, Mxico. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was founded in 1979 and is headquartered in Vancouver, Canada.
TickerPHMD [NASD]
CompanyPhotoMedex, Inc.
CountryUSA
IndustryMedical Appliances & Equipment
Market Cap43.60MEPS (ttm)-1.05
P/E-EPS this Y-17.60%
Forward P/E-EPS next Y57.70%
PEG-EPS past 5Y16.20%
P/S0.20EPS next 5Y15.00%
P/B0.31EPS Q/Q-
Dividend-Sales Q/Q17.00%
Insider Own5.60%Inst Own43.60%
Insider Trans57.67%Inst Trans-5.22%
Short Float27.62%EarningsNov 06/b
Analyst Recom2.80Target Price11.00
Avg Volume192.38K52W Range2.08 - 16.82
Nov-18-14 01:04PMPHOTOMEDEX INC Financials EDGAR Online Financials
Nov-12-14 07:09PM10-Q for PhotoMedex, Inc. Company Spotlight
Nov-10-14 01:04PMPHOTOMEDEX INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-06-14 08:30AMPhotoMedex Inc Earnings Call scheduled for 8:30 am ET today CCBN
Nov-06-14 07:35AMPHOTOMEDEX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Nov-06-14 07:35AMno!no! Hair Breaks Record on Home Shopping Television with the Most Units Sold on a Weekday Business Wire
Nov-06-14 07:30AMPhotoMedex Reports Third Quarter Financial Results Business Wire
Nov-06-14 07:07AMQ3 2014 PhotoMedex, Inc. Earnings Release - Before Market Open CCBN
Nov-04-14 04:30PMPHOTOMEDEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and EDGAR Online
Nov-04-14 02:12PMPhotoMedex Agrees to Amended Forbearance Agreement with Secured Creditors, Engages Canaccord Genuity to Evaluate Strategic Alternatives Business Wire
PhotoMedex, Inc., a skin health company, provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates in three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, including psoriasis, vitiligo, acne, and photo damage. The company also provides a range of home-use devices under the no!no! brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas. In addition, it offers XTRAC excimer lasers used for the treatment of psoriasis and other skin diseases; NEOVA skin care products for preventing premature skin aging due to ultraviolet-induced DNA damage; and Omnilux light therapy systems to treat wrinkles, acne, minor muscle pain, and pigmented lesions. Further, the company provides Lumire light therapy equipment for use in non-medical applications, as well as a line of topical lotions to improve the appearance of fine lines, wrinkles, skin tone, and blemishes. Additionally, it develops, manufactures, and sells surgical products, including proprietary free-beam and Contact Laser systems for surgery; sells surgical disposables and accessories to hospitals and surgery centers; and repairs, maintains, and replaces parts on its products. PhotoMedex, Inc. was founded in 1980 and is headquartered in Horsham, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rafaeli DolevCEOApr 01Sale15.3717,829274,082523,874Apr 03 03:26 PM
Rafaeli DolevCEOMar 11Sale15.0119,690295,448541,703Mar 11 04:53 PM
Rafaeli DolevCEOMar 10Sale15.063,60054,214561,393Mar 11 04:53 PM
Rafaeli DolevCEOMar 07Sale15.01101,7101,526,342564,993Mar 11 04:53 PM
Rafaeli DolevCEOMar 04Sale14.4169,326999,258666,703Mar 05 05:15 PM
TickerAXPW [NASD]
CompanyAxion Power International Inc.
CountryUSA
IndustryIndustrial Electrical Equipment
Market Cap11.80MEPS (ttm)-4.26
P/E-EPS this Y-21.80%
Forward P/E-EPS next Y-
PEG-EPS past 5Y27.40%
P/S1.55EPS next 5Y-
P/B1.31EPS Q/Q-
Dividend-Sales Q/Q-29.60%
Insider Own3.20%Inst Own6.70%
Insider Trans-90.34%Inst Trans-
Short Float0.46%Earnings-
Analyst Recom-Target Price-
Avg Volume42.38K52W Range1.24 - 11.50
Nov-22-14 01:04PMAXION POWER INTERNATIONAL, INC. Financials EDGAR Online Financials
Nov-17-14 07:30AMAxion Power to Present at the BOTU 2014 NYC Fall Conference PR Newswire
Nov-15-14 07:07PM10-Q for Axion Power International, Inc. Company Spotlight
Nov-14-14 07:30AMAxion Power Reports Results for Third Quarter and Nine Months of 2014 PR Newswire
Nov-13-14 04:32PMAXION POWER INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-11-14 07:30AMAxion Power Appoints Charles R. Trego Chief Financial Officer PR Newswire
Nov-10-14 04:32PMAXION POWER INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-06-14 07:30AMAxion Power Letter to Shareholders PR Newswire
Oct-30-14 10:36AMAxion Supplying Energy-Storage System to Pennsylvania Solar Farm at Bloomberg
Oct-30-14 09:22AMAxion Power Designated As Supplier Of Energy Storage And Frequency Regulation For 9.1 Megawatt Pennsylvania Solar Farm PR Newswire
Axion Power International, Inc. is engaged in the design, development, manufacture, and sale of advanced energy storage devices, components, and systems based on its patented PbC Technology. Its PbC batteries and components are used in energy system storage functions. The company also manufactures standard and specialty lead-acid batteries. Axion Power International, Inc. was founded in 2003 and is based in New Castle, Pennsylvania.
1 2 3 next